Content Please enter your email address and password:

Forgotten your password? Click here.

We are the Pharmacy Law & Ethics Association

Latest News

Results page: [Prev] 1 2 3 ... 6 7 8 9 10 11 12 ... 40 41 42 [Next]

GPhC enforcement policy for pharmacy premises

Posted: Wednesday, March 27th, 2019

The General Pharmaceutical Council has published an enforcement policy for registered premises 

The policy:

The policy states that the GPhC is committed to using the minimum regulatory intervention required to achieve the desired result, known as “right-touch regulation”.

In addition to setting out its enforcement options and the criteria for taking enforcement action, the GPhC refers to its powers under the Regulation of Investigatory Powers Act 2000 (known as “RIPA”) to carry out covert surveillance if authorised by a Director.  

The GPhC is expected to publish guidance on enforcement in the near future.

Claire Bryce-Smith, Director of Insights, Intelligence and Inspection at the GPhC, will address some of these issues in her presentation at our annual seminar on 9 April 2019 at the offices of Charles Russell Speechlys LLP, 5 Fleet Place, London EC4M 7RD. To book a free place, members should go to and log in.  Anyone who has forgotten their log in details should email

Judgment against GP set aside

Posted: Sunday, March 24th, 2019

In a News item on 11 December 2018, we reported on the case of Brayshaw v Partners in Apsley Surgery. It appears that the GP who was found to have been negligent had not been served with any of the court papers so the case against him proceeded in his absence. The GP only found out about the case when the judgment was drawn to his attention. In Brayshaw v Partners of Apsley Surgery [2018] EWHC 3286 (QB), the judgment against the GP was set aside, though the judgment in respect of the allegations against the partners in the Apsley Surgery remains intact.

Legal challenge to serious shortage protocols

Posted: Sunday, March 17th, 2019

The Human Medicines Regulations (HMR) were amended with effect from 9 February 2019.  The amendments implemented the Falsified Medicines Directive and gave ministers powers to introduce serious shortage protocols – see our News item of 20 January 2019.

The Good Law Project, a non-profit organisation that says it “fight[s] cases to defend, define or change the law” in the areas of Brexit, tax and workers’ rights, has applied for permission to bring judicial review proceedings to quash the serious shortage protocol powers.

The grounds of challenge (paraphrased) include:

Judicial review is a two-stage process.  If a judge, usually considering the papers without a hearing, considers that the claimant has an arguable case, permission will be given for a full hearing. The Good Law Project has asked for the papers to be considered urgently and for any full hearing to be expedited.

The DHSC has filed a document at the High Court with its grounds for resisting the judicial review application, contending that the Good Law Project lacks sufficient status to even bring the case, and that its grounds are not properly arguable. It points out that if the judicial review case succeeded, the UK would be left without an important tool by which the Secretary of State can address any serious drug shortages arising, including post Brexit.

David Reissner has written a blog on the judicial review application which can be read here 


Which country's professional standards apply?

Posted: Monday, March 11th, 2019

In Pantula Sastry v General Medical Council [2019] EWHC 390 (Admin), Mr Justice May heard an appeal by a medical practitioner against a decision to remove his name from the medical register.

Dr Sastry had worked at a hospital in India in 2013 and 2014.  He then worked in the UK for 4 years without incident.  It was alleged that his treatment of a patient in India had led to the patient’s death. The treatment was the subject of an allegation that the doctor was unfit to practise by reason of misconduct. The Medical Practitioner Tribunal determined the case according to UK Good Medical Practice.

Dr Sastry argued that the Tribunal failed to have sufficient regard to the context that practices, laws and standards in India, where the treatment had taken place, were different to those in the UK. The court held that when considering whether a registrant undertaking professional duties outside the UK had fallen short of standards of professional conduct which the UK public was entitled to expect from its doctors, a tribunal had to take into account any particular limitations or local practices which applied in the foreign location. However, since the GMC’s remit was to protect the public in the UK and to promote proper professional standards in the UK, it was bound to assess conduct with UK professional standards in mind.

Sexual misconduct - recent FtP cases

Posted: Sunday, February 3rd, 2019

Two recent fitness to practise cases in the High Court, both involving sexual misconduct, raise interesting issues.

In Nwapa v General Pharmaceutical Council [2019]WLUK 293 a locum pharmacist appealed against a decision to remove him from the register. He had been convicted of two offences of sexual assault against a colleague whom he had touched inappropriately on several occasions and threatened to follow home and had been given a suspended custodial sentence. At an interim hearing, conditions of practice were imposed, restricting him from undertaking Medicines Use Reviews, but had not informed his employer of the conditions and undertook MURs as usual.

There were some flaws in the reasons given by the Fitness to Practise Committee for its decision. It failed to mention a reflective statement written by the appellant, and when considering the appellant’s insight, the Fitness to Practise Committee had not mentioned that he had pleaded guilty in the Crown Court. However, Mr Justice Freeman held that the Committee was not required to deal explicitly with every point of evidence. For example, the absence of a mention of a guilty plea was not serious enough to show the kind of irregularity that would require the court to overturn the decision to strike off.  In any event, the late plea of guilty carried little weight.  The appeal was dismissed.

In General Medical Council v X [2019] 1 WLUK 255, the GMC appealed against the decision of the Medical Practitioners Tribunal Service to suspend X from practice, contending that the doctor should have been struck off. In R (on the application of X) v General Medical Council, the same doctor applied for judicial review of Tribunal’s decision that the determination should be published, albeit in redacted form.

The allegations arose because vigilantes, pretended online to be a 15-year old girl who had a 14-year old friend who was interested in having sex with X. A meeting was arranged but it did not take place. The vigilantes reported X to the police, who concluded that no offence had been committed but informed X’s employer who passed the information to the GMC, resulting in the Fitness to Practise proceedings.

X was a serious suicide risk. Because of X’s mental state, the proceedings were held in private. The Tribunal found X’s motive in the online communications was sexual, and that X’s explanation to the police and in the fitness to practise proceedings was untrue and dishonest. It held that X’s conduct amounted to serious misconduct and that X’s fitness to practise was impaired.  It suspended X for 12 months. X asked the GMC not to publish any part of the decision beyond saying that X had been suspended for 12 months for misconduct, because of X’s significant fear of X’s sexuality being revealed. X adduced expert evidence of X’s continued high suicide risk and how it would be exacerbated by the publication of the Tribunal’s decision. The GMC decided to publish the decision in full but redacted so as not to reveal X’s gender and sexuality.

It seems a little surprising that, after the recent Williams review of gross negligence manslaughter, in which a recommendation was made that the GMC should lose its right of appeal to the High Court, the GMC proceeded with an appeal. Mr Justice Soole rejected the appeal, holding that there was no basis for criticism of the Tribunal’s decision on sanction.  The Tribunal had taken into account that there had been no predatory behaviour or abuse of X’s position as a doctor.

X’s application for judicial review was granted because, despite the public interest in the GMC’s maintenance of a statutory public register, patient safety was met by the suspension and, when it came to balancing publication of the decision against the real and immediate risk of X’s suicide, X’s case was overwhelming.

Medicines shortage protocols and FMD - amendments to HMR

Posted: Sunday, January 20th, 2019

HMR amendment

The Department of Health has laid the Human Medicines (Amendment) Regulations 2019 before Parliament. The Regulations will amend the Human Medicines Regulations as from 9 February 2019.

Primarily, the amendments address two issues: medicines shortages and implementation of the Falsified Medicines Directive.

Medicines shortages – serious shortage protocols

Where a Minister believes that there is a serious shortage of a specific prescription only medicine (POM), the Minister may issue a written protocol (SSP) that provides for the sale or supply of:

SSPs will be developed with and signed off centrally by clinicians.  They may list what alternative products may be supplied by pharmacists without them having to go back to prescribers. Some products, such as those for the treatment of epilepsy, will not be covered by SSPs, and patients will have to be referred back to prescribers.

When a SSP has been issued, pharmacists will be freed from the legal requirement to supply only in accordance with a prescription, provided that they supply:

Conditions to be satisfied by pharmacists

Any sale or supply under a SSP must be made by or under the supervision of a pharmacist who is of the opinion, in the exercise of his or her professional skill and judgement, that:

Supplying an alternative POM without meeting the SSP conditions would involve the criminal offence of supplying otherwise than in accordance with a prescription.

If a patient is harmed by a permitted substitution, this may still be an offence under section 64 of the Medicines Act 1968.   

SSP review

The Regulations include a clause requiring a review of the serious shortage protocol as soon as is reasonably practical following the end of one year after the first such protocol starts to have effect. This will look at, specifically, any adverse consequences for either the market in prescription only medicines or patient safety. A stakeholder consultation will be conducted as part of the review.

SSP benefits?

DHSC believes the main benefits of the protocol would be the NHS cost savings associated with GP time, but acknowledges that there may be some risks to patients. DHSC expects that the impact on community pharmacies will be neutral. It believes there will be cost savings through pharmacies not having to liaise with GPs, but pharmacies will need to inform the GP when they dispense against a protocol and they may also be required to do some further checks that they would not do when dispensing against a prescription.

The changes relating to medicines shortages are not dependent on circumstances of Brexit and DHSC believes they will only be used in exceptional circumstances.

Falsified Medicines Directive

The Falsified Medicines Directive (FMD) will require medicines to bear a 2D barcode and an anti-tamper device. Pharmacies will have to verify the authenticity of medicines by scanning, and decommission medicines at the time of supply to a patient.

Breach of FMD will not automatically be an offence.  Instead, the MHRA can serve an enforcement notice specifying the breach and the measures to be taken in order to prevent continuation or repetition. Failure to comply with an enforcement notice will be a criminal offence.

MHRA updates no-deal Brexit guidance

Posted: Thursday, January 10th, 2019

The MHRA has updated its no-deal Brexit guidance. Key features of the guidance include:


The EU (Withdrawal) Act will ensure that existing EU rules are converted into UK law at the moment of exit, with changes where necessary to make sure the rules work in the UK.

Online pharmacies

The EU common logo for online sellers currently allows sale of medicines throughout EU countries and can be issued by the MHRA and other EU competent authorities. In order to sell into the EU, EU-based online sellers have to register, comply with relevant requirements and display an EU common logo linked to the competent authority in which they are based. As they would be outside of the EU, UK-based online sellers would no longer be required to do this. For the UK market, the MHRA proposes to explore requiring the use of new ‘UK logo’ for UK-based online sellers from 2021.

Manufacturing and wholesaling

In the event of a no deal scenario the UK proposes to continue using, until further notice, the EU Good Manufacturing Practice and Good Distribution Practice guidelines.

Parallel imports

If there’s ‘no deal’, the UK will unilaterally align to the EU/EEA exhaustion regime from Exit day to provide continuity in the immediate term for businesses and consumers and ensure that parallel imports of goods, such as pharmaceuticals, can continue from the EU/EEA.

All Party Parliamentary Group for Medicinal Cannabis

Posted: Thursday, January 10th, 2019

The Guardian has reported that the All Party Parliamentary Group for Medicinal Cannabis has said there is "a serious cultural block within the NHS around medicinal cannabis".

It appears that few clinicians have been willing to prescribe cannabis since the Misuse of Drugs Regulations were amended in November 2018, and the Group says this cannot have been what the government intended when it agreed to change the law.

The legal and ethical implications of medicinal cannabis will be the subject of a key presentation at our annual seminar on 9 April 2019.

2019 Seminar - 9 April - save the date

Posted: Wednesday, January 2nd, 2019

This year's Seminar will be held on 9 April 2019 at the offices of Charles Russell Speechlys, 5 Fleet Place, London EC4M 7RD.  Please save the date.  Presentations will include:


Pharmacy inspection and regulation

Posted: Tuesday, December 11th, 2018

Earlier this year, PLEA responded to the GPhC consultation on pharmacy inspection and regulation.  The GPhC has just published the outcome of its deliberations following the consultation.  In particular:

Results page: [Prev] 1 2 3 ... 6 7 8 9 10 11 12 ... 40 41 42 [Next]

These news items are not exhaustive but are selected according to their relevance to pharmacy practice, NHS community pharmacy contracts and the regulation of the pharmacy profession. If you wish to add any items that you think we have missed, contact our news editor.